BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, November 25, 2024
Breaking News: Healing a health divide (that’s long overdue)
See today's BioWorld Science
Home
» Insilico Medicine presents new CDK8/CDK19 dual inhibitors
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cancer
Insilico Medicine presents new CDK8/CDK19 dual inhibitors
Jan. 12, 2024
No Comments
Insilico Medicine IP Ltd. has divulged cyclin-dependent kinase 8 (CDK8) and/or CDK19 dual inhibitors reported to be useful for the treatment of autoimmune diseases and cancer.
BioWorld Science
Cancer
Patents
